Sugammadex
- Generic Name
- Sugammadex
- Brand Names
- Bridion, Sugammadex Adroiq, Sugammadex Amomed, Sugammadex Fresenius Kabi, Sugammadex Mylan, Sugammadex Piramal
- Drug Type
- Small Molecule
- Chemical Formula
- C72H112O48S8
- CAS Number
- 343306-71-8
- Unique Ingredient Identifier
- 361LPM2T56
- Background
Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general anesthesia, ventilation, or tracheal intubation that patients may require for surgery. Sugammadex provides a new treatment option to reverse the effects of those medications and possibly help patients recover sooner post-surgery. Sugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015.
- Indication
Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide in adults and pediatric patients ≥2 years old who are undergoing surgery.
- Associated Conditions
- Neuromuscular blockade caused by vecuronium bromide
The ED95 Dose of Sugammadex to Reverse Rocuronium-Induced Deep Neuromuscular Block Back to Shallow Neuromuscular Block
- Conditions
- Anesthesia, GeneralDeep Neuromuscular Blockade
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Ankara University
- Target Recruit Count
- 40
- Registration Number
- NCT05841316
Postoperative Sugammadex After COVID-19
- Conditions
- COVID-19General Anesthesia
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Korea University Ansan Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT05817019
Evaluating Outcomes in Cardiac Surgery Patients Who Receive Sugammadex vs. Placebo
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- NorthShore University HealthSystem
- Target Recruit Count
- 175
- Registration Number
- NCT05801679
- Locations
- 🇺🇸
NorthShore University HealthSystem, Evanston, Illinois, United States
Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex
- Conditions
- Urinary Retention PostoperativeLaparoscopic CholecystectomyNeuromuscular BlockadeNeuromuscular Blocking AgentsSugammadexNeostigminePhysiological Effects of Drugs
- Interventions
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 235
- Registration Number
- NCT05794503
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
An Observational Study to Analyze the Prescription Pattern of Sugammadex and Its Effectiveness and Safety
- Conditions
- Postoperative ComplicationsNeuromuscular BlockadeAnesthesia
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Boryung Pharmaceutical Co., Ltd
- Target Recruit Count
- 7000
- Registration Number
- NCT05788718
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Seongbuk-gu, Korea, Republic of
Incidence of Postoperative Residual Neuromuscular Blockade in the Era of Sugammadex
- Conditions
- Postoperative Residual Curarization
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT05760560
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of
Effectiveness on Smooth Extubation According to the Administration Time of Sugammadex
- Conditions
- ExtubationSugammadexSmooth Emergence
- Interventions
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Ajou University School of Medicine
- Target Recruit Count
- 66
- Registration Number
- NCT05751603
Diaphragm Function After Reversal of Rocuronium-induced Neuromuscular Blockade With Sugammadex or Neostigmine in Children
- Conditions
- Neuromuscular Block, Residual
- Interventions
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 73
- Registration Number
- NCT05724550
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Jongrogu, Korea, Republic of
The Immunomodulatory Effect of Sugammadex After Total Hip Replacement Surgery Under Neuraxial Anaesthesia: a Pilot Study
- Conditions
- Innate Inflammatory ResponseOsteoarthritis, Hip
- Interventions
- Other: Placebo
- First Posted Date
- 2023-02-10
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT05723406
- Locations
- 🇳🇱
Radboudumc, Nijmegen, Netherlands
Low Dose of Sugammadex vs Neostigmine and Glycopyrrolate for the Reversal of Rocuronium
- Conditions
- Neuromuscular Blockade
- Interventions
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Ciusss de L'Est de l'Île de Montréal
- Target Recruit Count
- 144
- Registration Number
- NCT05718934
- Locations
- 🇨🇦
CIUSSS de l'Est de l'Ile de Montreal, Montreal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.